trial · primary record
68-Gallium-DOTATATE-PET/CT
Metastic Thyroid Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 54 |
| Primary completion | 2030-11-30 |
| Primary endpoint | Prevalence of patients with metastatic RAI-non-avid or RAI-non-responsive thyroid cancer whose tumors are characterized by a high SSTR2 expression by imaging with 68Ga-DOTATATE PET/CT |
| Registry ID | NCT04927416 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:51.222Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04927416
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.